Holger Wesche
Hoofd Techniek/Wetenschap/O&O bij HARPOON THERAPEUTICS, INC.
Vermogen: 129 886 $ op 29-02-2024
Actieve functies van Holger Wesche
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| HARPOON THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-10-2018 | - |
Loopbaan van Holger Wesche
Eerdere bekende functies van Holger Wesche
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| AMGEN INC. | Hoofd Techniek/Wetenschap/O&O | 01-03-2013 | 01-04-2015 |
Opleiding van Holger Wesche
| University of Hannover | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Duitsland | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Beurs
- Insiders
- Holger Wesche
- Ervaring
